Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.34 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.34 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.34 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | MAX | P61244 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30896407 | 1.00 | GPR3 (0.45) | GPR3CYP1A2CYP2C19NOS1LCK | |
| SCHEMBL6921370 | 0.80 | JAK2 (0.41) | LCKTSHRMAP4K4CSF1RFGFR1 | |
| SCHEMBL6915290 | 0.80 | JAK2 (0.41) | FGFR1KDRDYRK1BDYRK1ACHEK1 | |
| SCHEMBL6920515 | 0.77 | CSNK2A1 (0.38) | MAP4K4CSF1RAURKBCLK4LMNA | |
| SCHEMBL6661870 | 0.76 | NISCH (0.33) | CYP1A2CYP2C19NOS1TSHRFGFR1 | |
| SCHEMBL6662853 | 0.76 | CSF1R (0.50) | MAP4K4CSF1RFGFR1PDGFRALTK | |
| SCHEMBL6913853 | 0.76 | NMT2 (0.43) | CYP1A2CYP2C19NOS1LCKTSHR | |
| SCHEMBL6919545 | 0.76 | NMT2 (0.49) | CYP1A2CYP2C19LCKTSHRMAP4K4 | |
| SCHEMBL6921256 | 0.72 | CDK2 (0.39) | AURKBCHEK1 | |
| SCHEMBL6917877 | 0.72 | ERN1 (0.40) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144870-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260124242-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12473532-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240392245-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-11-28 | — | — | US | disclosed |
| CN-113748202-B | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof | 艾欧凡斯生物治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20230340412-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | IOVANCE BIOTHERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230165898-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF | IOVANCE BIOTHERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230092130-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20220133795-A1 | Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof | IOVANCE BIOTHERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220118011-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
| CN-113748202-A | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof | 艾欧凡斯生物治疗公司 | 2021-12-03 | — | — | CN | disclosed |
| US-20200347350-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | IOVANCE BIOTHERAPEUTICS INC (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200224161-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
| CN-110832070-A | Expansion of liquid tumor-derived tumor infiltrating lymphocytes and therapeutic uses thereof | 艾欧凡斯生物治疗公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2019217753-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| WO-2004016615-A1 | PYRAZOLO (4,3c) CINNOLINE COMPOUNDS AS INHIBITORS OF ITK KINASE ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092130-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | PBK, MALT1, BCL9L | GPR3 4000/4885CYP1A2 4727/4885CYP2C19 3575/4885 |
| US-20200224161-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | PBK, MALT1, BCL9L | GPR3 4000/4885CYP1A2 4727/4885CYP2C19 3575/4885 |
| US-20230340412-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | LTK, LIFR, PBK | GPR3 2415/4885CYP1A2 4670/4885CYP2C19 3108/4885 |
| US-20260124242-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | PBK, LTK, BLK | GPR3 2597/4885CYP1A2 2857/4885CYP2C19 2118/4885 |
| US-20260144870-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | PBK, ITK, IL2 | GPR3 1555/4885CYP1A2 4252/4885CYP2C19 3908/4885 |
| US-20230165898-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF | CD47, LTK, PBK | GPR3 1820/4885CYP1A2 4386/4885CYP2C19 3281/4885 |
| US-20220133795-A1 | Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof | PBK, LTK, CD47 | GPR3 2251/4885CYP1A2 4409/4885CYP2C19 3084/4885 |
| US-20200347350-A1 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | LTK, LIFR, PBK | GPR3 2415/4885CYP1A2 4670/4885CYP2C19 3108/4885 |
| US-20240392245-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | PBK, MALT1, BCL9L | GPR3 4000/4885CYP1A2 4727/4885CYP2C19 3575/4885 |
| US-12473532-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | ICOS, PBK, IL2 | GPR3 4279/4885CYP1A2 4337/4885CYP2C19 4251/4885 |
| US-20220118011-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | ICOS, PBK, IL2 | GPR3 4279/4885CYP1A2 4337/4885CYP2C19 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.